Company intelligence / Profile preview

iLolay

Ownership: Private
Development stage: Other

Overview

The iLoF Platform provides rapid (<10 seconds), minimally invasive blood-based screening to stratify patients for clinical trials. It has demonstrated significant cost savings (~40%) and time reduction (~70%) in patient screening. The technology has been validated through partnerships with leading academic institutions and industry clients, with a primary focus on Alzheimer's disease but expanding into oncology and infectious diseases.

Therapeutic areas: OncologyNeurologyInfectious DiseasesOther
Modalities: Not directly therapeutic; enables and accelerates drug discovery and development for multiple modalities (e.g., small molecule, biologic) via digital biomarker profiling
Industry: Contract Research Organization

Partnerships

Academic collaborations with University College London, Maastricht University, Oxford University, Danish National Biobank

Beyond the preview

Go deeper on iLolay.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iLolay.

Explore the full profile